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Drug Eluting Stent (DES) in the treatment of Peripheral Arterial Disease in lower 
limbs in Colombia. Methods: An analytical decision model was considered with 
Target Lesion Restenosis (TLR) avoided and total cost at the end of a two year period 
as endpoints. An Excel model was developed. For the effectiveness data a Meta-
analysis was done and second revascularization procedures probabilities were taken 
with KOL criterion. A public payer perspective was assumed. Total costs were taken 
from reimbursement values charged to payers. Because effectiveness and cost were 
taken as unique values at the end of the two years with no cycles, discount rate 
was no applied. The sensitivity Univariate analysis was done for DEB vs. PTA. For 
the Probabilistic Sensitivity Analysis a Monte Carlo Simulation with 1000 iterations 
was done. Results: TLR Avoided probability with DEB was 0.86 vs. 0.60, 0.72 and 
0.81 for PTA, BMS and DES respectively. DEB total cost was US$4.441 vs. US$3.893 for 
PTA, US$4.826 for BMS and US$5.599 for DES. Respect to PTA, DEB ICER was US$2.142, 
US$7.776 for BMS and US$8.204 for DES. In univariate sensitivity the DEB ICER was 
especially sensible to total costs for both therapies and for the TLR probability for 
PTA. The Willingness-To-Pay (WTP) acceptability curves show that DEB, compared to 
other therapies, had a higher probability to be accepted for all the WTP values above 
US$2.500, reaching a probability of 94% for US$10.000 WTP value ConClusions: 
DEB have better cost-effectiveness ratio than PTA, with an ICER of US$2.142 and 
was dominant over BMS and DES. The univariate sensitivity analysis shows the 
ICER of DEB vs. PTA was especially sensible to the total costs of the therapies and 
the effectiveness of PTA.
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A Hybrid ComPArison of Cost-EffECtiVEnEss of trAnsCAtHEtEr AortiC 
VAlVE rEPlACEmEnt bEtwEEn rAndomizEd CliniCAl triAls And rEAl 
world PrACtiCE in trEAting PAtiEnts witH sEVErE AortiC stEnosis
Chu L.H.1, Hay J.1, Cohen D.J.2
1University of Southern California, Los Angeles, CA, USA, 2Saint Luke’s Mid America Heart 
Institute, Kansas City, MO, USA
objeCtives: To fill the knowledge gap of cost-effectiveness result between rand-
omized clinical trials and real world practice in treating patients with medically 
managed severe aortic stenosis, a hybrid comparison model, using a US societal 
perspective, was conducted. Methods: The cost-effectiveness of Transcatheter 
Aortic Valve Replacement (TAVR) was compared to medical management using the 
2010 PARTNER trial (Cohort B) result and 2003 Medicare claims analysis (compari-
son group) on a population with severe aortic stenosis (AS). Survival rate, quality of 
life , medical resource use and related hospital and physician cost were reported 
in the PARTNER trial. The Medicare claims analysis presented survival rate and 
overall cost in treating severe AS, which was converted to 2010 dollars. To calculate 
quality-adjusted life expectancy, and estimate the incremental cost-effectiveness, 
QALY for Medicare claims analysis was derived from the control arm of PARTNER 
trial. The effect of uncertainty in model parameters was examined through one 
way sensitivity analysis and probabilistic sensitivity analysis (PSA). Results: 
Over a two-year time horizon, in the base case the cost of TAVR was higher than 
the comparison group by $65,813. An additional 0.5 quality-adjusted life years 
was gained in the TAVR group. The resultant incremental cost-effectiveness ratio 
(ICER) was $ 132,155 per QALY gained for patients treated with TAVR vs. managed 
medically. Given $150,000 as the acceptability threshold for ICER willingness to pay, 
66.4% iterations in PSA were favorable toward TAVR. ConClusions: In real world 
practice where it is difficult to qualify patients with rigid criteria, our result shows 
that TAVR fell at the borderline of the cost effectiveness acceptability threshold. 
Although this study only considers the first two years of treatment, given the 
relatively short 2-3 year life expectancy of medically managed patients with severe 
AS, this result highlights the importance to have a strict guideline for TAVR to 
ensure its cost effectiveness.
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Cost-EffECtiVEnEss AnAlysis of AltErnAtiVE sCrEEning And 
trEAtmEnt strAtEgiEs for fAmiliAl HyPErCHolEstErolEmiA in tHE 
UnitEd stAtEs
Chen C., Hay J.
University of Southern California, Los Angeles, CA, USA
objeCtives: Familial hypercholesterolemia (FH) is a genetic disease that causes 
build-up of low-density lipoprotein cholesterol and premature coronary heart dis-
ease. Taken regularly, statins can lower cholesterol and risk of heart attack and 
stroke in FH individuals and high cholesterol individuals with no FH gene mutations. 
However, the US FH diagnosis rate is only 20% of actual cases, and patients gener-
ally have suboptimal statin adherence. Given cost-effectiveness studies evaluating 
genetic screening for FH in Europe, similar screening strategies with adherence 
programs could be cost-effective in the US. The objective of this study is to conduct 
a cost-effectiveness analysis of lipid cascade screening, genetic cascade screen-
ing, and lipid cascade screening plus statin adherence program for FH diagnosis 
and treatment in terms of incremental cost-effectiveness ratios (ICERs) between 
strategies. Methods: A Markov model with transition probabilities derived from 
published literature was used to model screening strategies. Because the model 
assumes an initial cohort of high cholesterol adults with a family history of FH, lipid 
cascade screening is the base case. US costs and quality of life data were obtained 
from published literature and public data. Results: Genetic cascade screening is 
dominated by base case screening, with an ICER of $532,222/QALY between the two. 
While the lifetime costs of statin adherence programs exceed the onetime costs 
of genetic testing, lipid cascade screening with statin adherence program is the 
most cost-effective strategy with an ICER of $10,705/QALY compared to the base 
case. At a US willingness-to-pay of $150,000/QALY, net monetary benefit analysis 
suggests that genetic cascade screening will only produce non-negative benefits 
at screening costs of less than $1,700 per diagnosed case. ConClusions: Genetic 
cascade screening for FH is not cost-effective in a US setting. The addition of statin 
adherence programs is cost-effective, but lack of US FH studies suggests a need for 
further analyses.
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ComPArAtiVE EffECtiVEnEss And Cost-EffECtiVEnEss of CArotid 
ArtEry stEnt witH Emboli ProtECtion dEViCE VErsUs CArotid 
EndArtErECtomy: A rEtrosPECtiVE CoHort stUdy Using nHi ClAims 
dAtAbAsE in tAiwAn
Wang J.C., Liao C.H., Wang Y.C., Gau C.S.
Center for Drug Evaluation, Taipei, Taiwan
objeCtives: The objectives were to compare the effectiveness and cost-effectivness 
of carotid artery stent with emboli protection device (CAS+EPD) and carotid endar-
terectomy (CEA). Methods: A retrospective cohort during 2001-2012 was built 
using NHI database. Outcomes events cumulative incidence rate of death, stroke, 
death or stroke, and MI occurring 30 days peri-procedure, 1 year and 8 years after 
procedure, were analyzed as comparative effectiveness. The transitional probabili-
ties of various outcomes were adopted from comparative effectiveness results by 
Weibull distribution. Kaplan Meier sample average method was applied for medical 
cost. A Markov model was built to simulate the lifetime QALYs and medical costs 
estimation. Results: A total of 3,359 and 543 patients were included in CAS+EPD 
and CEA groups. In comparative effectiveness, the incidences of safety outcomes 
in stroke (2.2% vs. 2.0%), death (0.7% vs. 1.5%), and death or stroke (2.7% vs. 2.9%) 
did not differ significantly between CAS+EPD and CEA within 30 days post proce-
dure. A one-year follow-up revealed that CEA was associated with higher risks of 
stroke (hazard ratio: 2.72, 95%CI: 1.61-4.61) and death or stroke (HR: 2.00, 95%CI: 
1.33-3.02) than CAS+EPD. Long term follow-up results demonstrated CEA had a 
higher risk in stroke (HR: 1.61, 95%CI: 1.09-2.37) only. The hospitalization cost were 
$5,600±2,500 in CAS+EPD and $ 4,800±6,100 in CEA, the total medical expense during 
the first year were $11,600 and $10,000, respectively. Life-long medical cost estima-
tion revealed $28,700 for CAS+EPD and $31,300 for CEA. Cost-effectiveness analysis 
showed CAS+EPD had 0.59 life years (LYs) gained better than CEA (9.24 LYs vs. 8.65 
LYs). The QALYs for CAS+EPD and CEA were 8.12 and 6.99, respectively. Overall, 
the results demonstrated CAS+EPD to be the dominant strategy. ConClusions: 
Retrospective cohort database analysis demonstrated CAS+EPD was more effective 
and also less expensive than CEA. Under current NHI reimbursement, the CAS+EPD 
was a cost-effective strategy.
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Cost-EffECtiVEnEss of dAbigAtrAn for strokE PrEVEntion in AtriAl 
fibrillAtion in CHinA
Wan Y.1, Davies G.M.2, Lu Z.G.3, Chen F.1, Chen J.4
1Nanjing Medical University, China, 2Merck & Co. Inc., Upper Gwynedd, PA, USA, 3Brigham and 
Women’s Hospital, USA, 4Merck & Co, Inc., North Wales, PA, USA
objeCtives: Warfarin has been the standard oral anticoagulant for stroke preven-
tion in patients with atrial fibrillation (AF). However, it has an increased risk of 
bleeding and a narrow therapeutic range which required frequent monitoring of the 
International Normalized Ratio (INR) and dose adjustments. Dabigatran, a novel oral 
anticoagulant, has demonstrated to be at least as effective and as safe as warfarin, 
and shown to be cost-effective in Canada and UK. Recently, dabigatran received 
approval in China. In this study, we aim to assess the potential cost-effectiveness 
of dabigatran for the prevention of stroke and systemic embolism among patients 
with AF as compared to warfarin as a first-line therapy, from the payer perspec-
tive in China. Methods: An individual level simulation model was developed to 
simulate the clinical events and outcomes under different treatment pathways over 
a patient’s remaining lifetime. The model explicitly incorporated an INR control 
component to account for heterogeneous use of warfarin in different populations 
and in settings. Input data were derived from the published literature, NICE STA 
reports, and expert inputs. Patient baseline profiles were based on China Registry 
of AF (CRAF), a multicenter, cross-sectional study of 3551 AF patients in mainland 
China. Results: Comparing to warfarin first-line use among patients eligible for 
anticoagulants, dabigatran was associated with 0.40 fewer ischemic stroke, 0.11 
fewer systemic embolism, 0.19 fewer hemorrhagic stroke, 0.30 fewer intracranial 
hemorrhage, 1.33 more extra-cranial hemorrhage and 0.38 more acute myocardial 
infarction, per 100 patient-year. Predicted incremental costs and QALYs are US$ 
13527.88 and 0.23, respectively, resulting an ICER of US$ 59546.08 per QALY gained. 
The result was sensitive to the cost of dabigatran cost, warfarin-related cost, and INR 
control assumptions. ConClusions: The cost-effectiveness of new anticoagulation 
therapy should be considered when making treatment recommendations. Further 
economic evaluation of appropriate use of dabigatran in China setting is needed.
PCV73
Cost EffECtiVEnEss of minimAlly inVAsiVE CArdiAC sUrgEry VErsUs 
ConVEntionAl APProACH in CArdiAC VAlVE sUrgiCAl rEPlACEmEnt in 
ColombiA
Gonzalez N.1, Londoño V.2, Orozco J.J.3, Valencia J.E.3
1Cardiovid Clinic, Medellin, Colombia, 2Sura EPS, Medellin, Colombia, 3Medtronic Latinamerica 
Inc., Bogota, Colombia
objeCtives: Cost-Effectiveness analysis of Minimally Invasive Cardiac Surgery 
(MICS) vs. Conventional Approach (CA) for surgical valve replacement in 
Colombia. Methods: An analytical decision model was considered with any imme-
diate severe complication avoided and total cost at the end of the hospitalization as 
the endpoint results. A deterministic and probabilistic Excel model was developed. 
Complications rates and costs were taking from 240 registries in a period of time 
between 01-2010 and 10-2012, from Cardiovascular Clinic Cardiovid at Medellin 
Colombia. Colombian Health System payer perspective was assumed and reim-
bursement prices were considered as the final costs for the procedures, including 
those until hospital discharge. Because only one cycle was considered there was no 
need to apply a discount rate. The deterministic ICER calculations analysis was done 
including a univariate sensitivity analysis. For the Probabilistic Sensitivity Analysis a 
Monte Carlo Simulation with 1000 iterations was done. Results: The complications 
avoided probability with MICS was 0.73 compared to 0.57 with CA. The total cost 
was US$14.330 for MICS compared to US$ 13.006 for CA with an ICER of US$ 8.326 
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for any avoided severe complication. In the univariate sensitivity analysis the ICER 
result was especially sensible to CA total cost and in a lesser extension to MICS total 
costs. The probabilistic sensitivity analysis shows the robustness of the results. The 
37.8% of the results were cost saving respect to CA. The Willingness To Pay (WTP) 
acceptability curves show that MICS compared to CA, had a higher probability to be 
accepted for the all the WTP values above US$16.000. ConClusions: MICS shows 
a better cost-effectiveness ratio than CA, with an ICER of US$8.326. The univariate 
sensitivity analysis shows the ICER result was especially sensible to CA total costs. 
The probabilistic analysis shows that in 36.8% of Monte Carlo simulations, MICS 
was cost saving respect to CA.
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EConomiC EVAlUAtion of CloPidogrEl VErsUs tiCAgrElor, in PAtiEnts 
witH ACUtE CoronAry syndromE, from tHE PErsPECtiVE of tHE 
mExiCAn PUbliC HEAltH CArE systEm
Reyes-Lopez A.1, Camacho-Chairez A.2, Gonzalez-Diaz B.3
1Mexican Children Hospital, Mexico City, Mexico, 2Sanofi Mexico, Mexico, Mexico, 3Mexican 
Institute of Social Security, Mexico, Mexico
objeCtives: To compare clopidogrel/aspirin with ticagrelor/aspirin in terms of 
costs and effects, from the perspective of the Mexican public health care sys-
tem. Methods: A markov model was designed to take into account all relevant 
outcomes reported in the PLATO study, allowing the evaluation of two differ-
ent cohorts of patients according to their renal function (< 60 mL/min creatinine 
clearance and ≥ 60 mL/min). The effectiveness measures analyzed were life years 
gained and events (bleeding, stroke and MI) averted. Annual cost of antiplatelet 
therapy was estimated with unit prices of the IMSS, while costs of diseases were 
taken from DRGs of the IMSS. 5 years horizon was used, so future costs were dis-
counted at 5% discount rate. Probabilistic sensitivity analysis was performed with 
1000 iterations via Monte Carlo simulations. Results: Total expected costs per 
patient were US$17,121 and US$17,697 respectively for both cohorts of clopidogrel 
while the costs for the two cohorts of ticagrelor were US$18,430 and US$18,261 
respectively. The treatment with clopidogrel resulted in less outcomes per patient 
(bleeding: 0.67 and 0.55; stroke: 0.09 and 0.083; MI: 0.51 and 0.49) than ticagrelor 
(bleeding: 0.76 and 0.59; stroke: 0.1 and 0.085; MI: 0.53 and 0.5); therefore the 
pharmacoeconomic profile of clopidogrel in comparison with ticagrelor is more 
favorable in the current study. Sensitivity analysis showed that clopidogrel has a 
higher probability of being a cost-saving option versus ticagrelor for both cohorts 
of patients. ConClusions: The economic evaluation of clopidogrel/aspirin ver-
sus ticagrelor/aspirin, taking into account relevant outcomes as well as primary 
endpoints of clinical trials, has proven that cost-effectiveness results may vary 
depending of the renal function of patients, thus giving a broader picture of the 
problem to decision makers.
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PHArmACoEConomiC AnAlysis of dAbigAtrAn in PAtiEnts witH AtriAl 
fibrillAtion: ComPArison witH riVAroxAbAn or APixAbAn
Gay-Molina J.G.1, Herran S.2, Sorensen S.3, Gonschior A.K.4
1TI Salud, Mexico, Mexico, 2Boehringer Ingelheim, Mexico, Mexico, 3Evidera, Bethesda, MD, USA, 
4Boehringer-Ingelheim GmbH, Ingelheim Am Rhein, Germany
objeCtives: To compare the incremental cost-effectiveness ratio (ICER) of the 
reversible direct thrombin inhibitor dabigatran 150mg BID with those of the Xa 
factor inhibitors rivaroxaban and apixaban from the Mexican public health insti-
tution perspective. Methods: The ICER´s were calculated using a Markov model 
with a 10-year time horizon for patients over 65 and diagnosed with atrial fibril-
lation. Each treatment arm started with a cohort of 10,000 patients. The clinical 
events tracked were incorporated: ischemic stroke, systematic embolism, transient 
ischemic stroke, hemorrhagic stroke, intracranial hemorrhage, extracranial hemor-
rhage, acute myocardial infarction, minor bleed and death. Transition probabilities 
were calculated based on indirect comparisons of published phase III clinical tri-
als. Costs are adapted to the Mexican public health institution perspective. Costs 
were calculated using published literature, and national costs taken from pharma-
ceutical companies and public health institutions. Cost-effectiveness was based 
on the 1GDP per capita threshold established by the National Health Council in 
Mexico. Costs and outcomes were discounted at a 5% annual-rate. Deterministic 
and probabilistic sensitivity analyses were performed to evaluate the uncertainty 
of the variables. Results: Dabigatran was found to be dominant when compared 
with rivaroxaban and apixaban. A reduction on risk for cardiovascular complica-
tions was the key advantage of dabigatran. Dabigatran was also more effective when 
compared with warfarin (69,435 vs. 68,373 life years gained) although more costly 
(USD$192.76 vs USD$190.73 million dollars). The ICER was USD $1,910.43 per life year 
which is considered highly cost-effectiveness. The Incremental Cost-Utility Ratio per 
QALY gained was USD$1,549.00. ConClusions: The ICER and ICUR of Dabigatran 
are well below 1GDP (USD$ 10,483.26) per capita versus warfarina. Dabigatran was 
found to be dominant in comparison with all other treatments. As such, dabigatran 
can be considered a very cost-effective intervention for the Mexican population 
over 65 with atrial fibrillation.
PCV76
EConomiC AssEssmEnt of tHE UsE of trAnsCAtHEtEr AortiC VAlVE 
rEPlACEmEnt in inoPErAblE stEnotiC PAtiEnts in mExiCo
Kumar G.1, Eaton J.N.2, Ceballos R.3, Gay J.G.4, Tierrablanca L.E.5
1ICON Health Economics, Oxford, UK, 2Oxford Outcomes Ltd, Oxford, UK, 3Medtronic, Mexico, UK, 
4TI Salud, Mexico, Mexico, Mexico, 5TI Salud, Mexico, Mexico
objeCtives: To identify the incremental cost-effectiveness ratio (ICER) for the 
treatment of inoperable patients with severe symptomatic aortic valve stenosis 
(SAS) using transcatheter aortic valve replacement (TAVR), compared to the stand-
ard of care (SoC), from the Mexican public payer perspective. Methods: A previ-
ously published decision analytical model was adapted to the Mexican setting to 
predict clinical endpoints and costs over 10 years and discounted at 5%. Mexican 
epidemiological data were applied. We performed a systematic review of published 
clinical trials to obtain the necessary clinical information to evaluate the impact 
of TAVR and SoC in the short and long term evolution of patients. Direct public 
health care costs were estimated from published literature and governmental data-
bases. Resource utilization patterns were derived from Mexican Clinical Practice 
Guidelines. The ICER was computed as incremental cost per life-year gained (LYG). 
Probabilistic and deterministic sensitivity analyses were conducted to estimate 
the confidence around the results. Results: Over the time horizon, compared 
to SoC, TAVR produced an additional 1.61 Life years at an additional cost to the 
health care sector of $777,414 MXP. The ICER was thus $483,022 MXP (35,779 USD) 
per LYG. The sensitivity analysis identified time horizon, discount rate on health 
benefits, probability of leaving intensive care and time of stay in intensive care, 
as the variables with the most impact. The model was insensitive to changes in 
the TAVR acquisition cost, device related complication rates and the probability/ 
cost of additional pacing. ConClusions: In comparison with SoC, TAVR produces 
an increase in life expectancy in patients with SAS that are ineligible for cardiac 
surgery, at an ICER below an internationally accepted cost-effectiveness threshold 
value. These results, and the improvements in health and quality of life observed 
in the clinical studies, identify TAVR as both a clinically effective and cost-effective 
therapy for Mexican patients.
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Cost EffECtiVEnEss of APixAbAn, dAbigAtrAn riVAroxAbAn And 
wArfArin for AtriAl fibrillAtion in gUAtEmAlA
Garita M.1, Peralta M.1, Gordillo D.I.2
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Hospital Universitario 
Esperanza, Guatemala, Guatemala
objeCtives: Atrial Fibrillation (AF) affects 1–2% of the population, and this figure 
is likely to increase in the next 50 years. AF is associated with increased rates of 
death, stroke and other thromboembolic events, heart failure and hospitaliza-
tions, degraded quality of life and reduced exercise capacity. It is suggested that 
patients with AF should be stratified for the risk of stroke and bleedings and that 
most should receive antithrombotic therapy. The aim of this study was to assess 
the cost-effectiveness (CE) of Apixaban against other anticoagulation therapies for 
prevention on non-valvular atrial fibrillation (NVAF), from the private health care 
perspective. Methods: A simulated cohort of 1000 patients with NVAF entered 
a decision-tree model to compare costs and effectiveness of Warfarin (5 mg/24 
hours), Apixaban (5 mg/12 hours), Dabigatran (110 mg/12 hours and 150 mg/12 
hours), and Rivaroxaban (20 mg/24 hours). Effectiveness measures were: stroke, 
bleeding, myocardial infarction (MI) rates and deaths. Local costs were gathered 
from Guatemala’s official databases (US$, 2013) and only direct medical costs were 
considered. The model used a lifetime horizon with a 5% discount. Results: 
Apixaban was the only treatment that consistently prevented all four consid-
ered diseases: 3 MIs, 4 strokes, 85 bleedings and 1 SE avoided when compared to 
Warfarin. Overall costs were US$33708.34 for warfarin, US$24538.68 for Apixaban, 
US$24757.57 for Dabigatran 110 mg, US$24198.23 for Dabigatran 150 mg, and 
US$24252.46 for Rivaroxaban. In terms of QALY’s, Apixaban earned the highest 
amount with 5.740, followed by Rivaroxaban, Dabigatran 150 mg, Dabigatran 110 
mg and Warfarin. In the CE incremental analysis, Apixaban was a cost-effective 
option. Apixaban obtained the highest probability of being cost-effective (45%) 
with a 3 GPB per capita in Guatemala. ConClusions: Apixaban is a Cost-Effective 
option for the Guatemala’s Private Health System.
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tHE Cost–EffECtiVEnEss of riVAroxAbAn for tHE PrEVEntion of 
CArdioVAsCUlAr (CV) EVEnts in PAtiEnts witH ACUtE CoronAry 
syndromE (ACs) in tUrkEy
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1Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Yorum Consultancy, ISTANBUL, Turkey, 
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objeCtives: To evaluate the cost-effectiveness of rivaroxaban in addition to the 
standard of care (SoC) therapy in the prevention of the risk of CV events and 
bleeding in patients with a recent ACS compared to the placebo in addition to the 
SoC. Methods: A Markov model demonstrating the progression of ACS patients 
from healthy state towards atherosclerotic and bleeding events and to death was 
adapted to the Turkish setting. The cycle length was set as six-months. The analy-
sis was undertaken from a payer perspective. Event rates and treatment effects 
were derived from the ATLAS-2-TIMI clinical trial. 61Utility values for events were 
based on international literature. Costs of each health state included year 2013 
local costs of medications, monitoring and events (TL/ USD currency rate was set 
at 1.70; mid 2013). Incremental cost effectiveness ratios (ICER) per life year (LY) and 
quality-adjusted LY (QALY) gained were calculated. One-way sensitivity analyses 
were conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. Willingness-
to-pay (WTP) threshold was set as twice the local gross domestic product per 
capita (20,888USD). Results: The total cost of rivaroxaban-treated patients was 
578USD higher compared to SoC. Additional drug costs (676USD) caused by rivar-
oxaban was somewhat offset by reduced costs of and events and interventions 
(98USD). Moreover, rivaroxaban was associated with increments of 0.102LYs and 
0.088QALY leading to an ICER of 5,691USD/LY gained and 6,590USD/QALY gained. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensi-
tive to most inputs. ConClusions: Rivaroxaban, given its cost-saving effects on 
consequent CV events, improvement in LYs and QALYs, and ICER values below 
WTP threshold, is suggested to be a cost-effective alternative for the prevention 
of CV events in ACS.
